Snapdragon Chemistry, Inc.

Snapdragon Chemistry, Inc. is a specialized provider of custom development services for pharmaceutical active pharmaceutical ingredients (APIs), enhancing efficiency in the drug development lifecycle. Founded in 2014, Snapdragon Chemistry, Inc. is based in Waltham, US.

The company focuses on providing custom development services for pharmaceutical APIs. Co-founded by Aaron Beeler and Tim Jamison, Snapdragon has engaged in 1 deal, with the most recent occurring on November 21, 2022. Snapdragon Chemistry specializes in custom development services for pharmaceutical active pharmaceutical ingredients (APIs) across all stages of the drug lifecycle. The company offers lab-, kilo-, and pilot-scale manufacturing solutions tailored to meet the needs of preclinical studies through to all phases of clinical trials, supplying quantities from milligrams to kilograms.

Their core competencies include advanced solid-phase and liquid-phase peptide synthesis, addressing the rising demand for peptide-based therapeutics. The company also provides unique technologies for seamless process development, reactor design, and analytical testing, enhancing the production processes' efficiency and reliability. Their customers include pharmaceutical companies in North America, Europe, and Asia, focusing on those engaged in drug development and production. Snapdragon Chemistry operates through a business-to-business (B2B) model, primarily serving pharmaceutical companies with custom API development services and manufacturing solutions.

Revenue streams are generated from partnerships and contracts for drug substance manufacturing, technology transfer, and analytical testing services, structured as project-based contracts, often leading to long-term collaborations throughout the drug development lifecycle. The company's flagship offerings include proprietary technologies aimed at optimizing complex synthetic processes critical for clients advancing their molecules in the competitive pharmaceutical landscape. Pricing structures reflect the bespoke nature of their services, with costs determined based on the scope and complexity of each project. In November 2022, Cambrex Corporation, a portfolio company of Permira, agreed to acquire Snapdragon Chemistry, Inc.

The acquisition aims to accelerate Cambrex Corporation's growth in continuous flow process development and manufacturing, while also expanding its portfolio of specialized solutions for pharmaceutical development and manufacturing. This strategic move will enhance Snapdragon's capabilities and reach in the pharmaceutical sector.